The epidermal growth factor receptor (EGFR) remains the only validated molecular target in head and neck squamous cell carcinoma (HNSCC), mediating cell survival signaling and resistance to radiation therapy.
Yale Head and Neck Cancer SPORE
Specialized Program of Research Excellence (SPORE) sponsored by the National Cancer Institute
Yale Cancer Center was awarded a five-year, $11.7 million grant from the National Institutes of Health (NIH) to fund the Yale Head and Neck Cancer Specialized Program of Research Excellence (SPORE). The SPORE program harnesses the strengths of academic cancer centers by bringing together experts in oncology, immunobiology, pharmacology, molecular biology, pathology, epidemiology, and addiction science to collaborate on projects. The goal of the Yale Head and Neck Cancer SPORE (YHN-SPORE) is to address critical barriers to treatment of head and neck squamous cell carcinoma (HNSCC) due to resistance to immune, DNA damaging, and targeted therapy.
Projects
PROJECT 1: Improved targeting of EGFR family members in squamous cell carcinomas of the head and neck PROJECT 2: Synthetic lethal therapy for HPV-negative head and neck cancer HPV-negative head and neck squamous cell carcinomas (HNSCC) typically lose G1/S cell cycle checkpoints, with most tumors having mutations in TP53, and many also mutating other tumor suppressors such as CDKN2A.Read MorePROJECT 3: Demethylation of HPV-associated head and neck cancer to trigger APOBEC synthetic lethality and enhance immune response Human papillomavirus (HPV)-associated neck squamous cell carcinoma (HNSCC) represents an increasing proportion of HNSCC.Read More
Latest News
- November 12, 2025
Twenty-Seven YSM Faculty Members Recognized for Highly Cited Research
- October 10, 2025
‘Google Maps’ Approach to Revolutionize Lung Cancer Treatment
- October 07, 2025
Multi-Day Cancer Symposium Lays Groundwork for Research Collaboration
- October 03, 2025Source: Cancer Network
Exploring the Next Frontier of Cancer Biomarkers in Precision Medicine
- October 03, 2025Source: Cancer Network
Looking Beyond Genomics to Advance Precision Medicine in Cancer Care
- October 01, 2025Source: Cancer Network (with Dr. David Rimm)
Advancing AI in Pathology, Precision Medicine, and the Melanoma Landscape
- September 30, 2025
Celebrating 50 Years: Yale Cancer Center
- August 25, 2025Source: WTNH
Yale Cancer Center Researchers Using AI in Melanoma Research
- August 20, 2025Source: NBC Connecticut (with Dr. David Rimm and Thazin Aung)
Could AI soon help people with cancer?
- August 04, 2025Source: Healio (with Dr. David Rimm)
Assay has ‘huge potential’ directing antibody-drug conjugate treatment for breast cancer
- July 17, 2025
The Pulse of Life: YSPH Study Reveals How Gene Expression Evolves
- July 17, 2025Source: Cancer Therapy Advisor (with Dr. Barbara Burtness)
Opinion: Perioperative ICIs Represent New Standard for HNSCC